Olmesartan Expiry In Mind As Daiichi Sankyo Shakes Up

26 Feb 2015

Major Japanese firm Daiichi Sankyo has unveiled a fundamental shakeup across its corporate structure that will see a cut in the number of divisions and simplification of reporting lines, as it battens down and cuts costs ahead of olmesartan's loss of exclusivity.

The sweeping changes are part of a broader effort by Daiichi Sankyo Co. Ltd. to reduce expenses and ensure growth under a five-year mid-term strategic plan that runs to the end of fiscal 2017 (in March 2018) and calls for a group operating profit margin of 15%-plus and a roughly 10% reduction in selling, general and administrative spending.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.